The Gam-COVID-Vac vaccine intends to reduce the time taken for the actual development of immunity to SARS-CoV-2 coronavirus, the virus behind the COVID-19 pandemic.
Six vaccines are already in Phase 3 of human trials or are about to enter. Sometimes, it also means that it could have a longer, sustained immune response.
The minister, who did not give details about the vaccine to be used, said doctors and teachers would be the first to be vaccinated.
Pharmaceutical giant AstraZeneca has also said that coronavirus might require annual vaccination.
The Drugs Controller General of India has given the Serum Institute of India a green light to conduct phase 2 and 3 human trials of the Oxford-AstraZeneca COVID-19 vaccine candidate in India. The approval was granted late Sunday night after a thorough evaluation based on the recommendations of Subject Expert Committee (SEC). The report highlighted that the firm conducting clinical trials of potential Coronavirus vaccine in India will have to submit the safety data to the CDSCO which will be first evaluated by the Data Safety Monitoring Board (DSMB), before Phase III clinical trials are initiated.
"As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals", an official told Press Trust of India. The human trial phases consist of Phase 1 for safety, Phase 2 for efficacy and dosing, and Phase 3 for efficacy in a huge group of tens of thousands of people. The COVID-19 vaccine candidate has been developed by Gamaleya Institute in Moscow.
Russian health authorities are preparing to start a mass vaccination campaign against coronavirus in October, the health minister has said.
Russian Federation said Monday it aims to launch mass production of a coronavirus vaccine next month and turn out "several million" doses per month by next year.
There is now no vaccine to prevent the spread of COVID-19.
Meanwhile, Russia is now developing a candidate vaccine.
"We will be able to ensure production volumes of several hundred thousand a month, with an eventual increase to several million by the start of next year", he said, adding that one developer is preparing production technology at three locations in central Russian Federation.